Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2026Clinical PharmacokineticsOpen Access

Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMahipal SinnollareddyKSKinjal SanghaviLGLeonid Gibiansky

Discussion

Loading...

Member takes

Overview

Randomized trial analyzes dosing regimen outcomes in relapsed follicular lymphoma, suggesting improved response rates with optimized dosing.

Key Points

  • This research aims to determine the optimal dosing regimen of epcoritamab for relapsed or refractory follicular lymphoma.
  • Conducted phase I/II study with a focus on dosing regimens and response rates.
  • Evaluated a 2-step and a new 3-step step-up dosing regimen.
  • Utilized exposure–response analyses to assess efficacy and safety profile.”],
  • The 3-step SUD regimen showed lower cytokine release syndrome (CRS) severity compared to the 2-step regimen.
  • Epcoritamab exposure correlated with higher response rates (ORR = 95.2%) and better overall survival (p < 0.05).
  • Median IL-6 levels remained consistently low after Cycle-1 doses in the 3-step regimen.

Cite This Study

Sinnollareddy et al. (2026) studied this question.

synapsesocial.com/papers/6a70402f75942ff7265e4ea5https://doi.org/10.1007/s40262-026-01661-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study2025
  2. 2Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025 · 14 citations
  3. 3Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  4. 4EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.2024 · 10 citations
  5. 5Epcoritamab Step‐Up Dosing Regimen Selection and Optimization Using Repeated Time‐to‐Event Modeling for Cytokine Release Syndrome Risk Mitigation2026